Image Analysis Group (IAG), a leader in clinical trial imaging and AI-driven biomarkers, has announced the opening of a new office in Cambridge, Massachusetts, marking a significant expansion of its U.S. operations. This strategic move positions the company closer to the biotechnology and pharmaceutical hubs in the Boston area, enhancing its ability to forge stronger partnerships and provide localized support for clinical trials in the region.
The Cambridge office will bolster IAG’s capabilities across various therapeutic domains, including oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. The proximity to key industry players enables IAG to collaborate more efficiently with sponsors and contract research organizations involved in Phase I–III clinical trials and imaging-centric development projects. Furthermore, IAG intends to contribute to the local job market by hiring talent in clinical imaging operations, data science, regulatory support, and business development over the next year or two.
By offering comprehensive imaging services such as clinical trial design consultation, optimization of imaging protocols, centralized image analysis, and regulatory-compliant data delivery, the new office aims to provide end-to-end support for clinical trials. IAG’s integration into the Boston life-sciences ecosystem is expected to enhance collaboration with biotechnology firms, pharmaceutical companies, academic institutions, and clinical research centers.
Globally, IAG operates across North America, Europe, and the Asia-Pacific region, working with pharmaceutical, biotechnology, and medical technology companies, as well as contract research organizations, on multi-center studies. The company’s global operations are structured to deliver standardized imaging protocols, centralized data harmonization, and consistent imaging analysis for international trials.
Since its founding in 2007, IAG, headquartered in London, has functioned as an imaging Clinical Research Organization (iCRO), supporting the pharmaceutical, biotechnology, and medical technology sectors with imaging-based clinical trial endpoints. The company’s DYNAMIKA™ platform combines AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight, making it a pivotal player in advancing clinical research methodologies.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.